TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial

H Hubert Tseng B Bhagirathbhai Dholaria S Stacey A. Cranert M Maximilian Richter K Karl S. Marquez B Benjamin S. Cho A Andrew Bacong K Katherine McArthur J Jeff D. Eskew J Joanne McCaigue S Sabrina Haag A Aly Krasny B Brian Solimine M Michael J. Coffey A Aimee Loyola J Jasmine Kwong L Leyla Shune A Andrew Kin C Caitlin L. Costello M Mehmet H. Kocoglu A Aravind Ramakrishnan H Hamid Namini C Christopher E. Martin R Rajesh Belani J Julia Coronella D Devon J. Shedlock

Article Details

Volume / Issue Vol. 16, Issue 1
Published November 24, 2025
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (26)

H

Hubert Tseng

B

Bhagirathbhai Dholaria

S

Stacey A. Cranert

M

Maximilian Richter

K

Karl S. Marquez

B

Benjamin S. Cho

A

Andrew Bacong

K

Katherine McArthur

J

Jeff D. Eskew

J

Joanne McCaigue

S

Sabrina Haag

A

Aly Krasny

B

Brian Solimine

M

Michael J. Coffey

A

Aimee Loyola

J

Jasmine Kwong

L

Leyla Shune

A

Andrew Kin

C

Caitlin L. Costello

M

Mehmet H. Kocoglu

A

Aravind Ramakrishnan

H

Hamid Namini

C

Christopher E. Martin

R

Rajesh Belani

J

Julia Coronella

D

Devon J. Shedlock